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PATIENT’S SOCIOECONOMIC STATUS AS A PROGNOSTIC FACTOR FOR
ALLOGENEIC STEM CELL TRANSPLANTATION
Silla, L., Fischer, G., Mitto, I., Grossini, M., Bittencourt, H.,
Astigarraga, C., Daudt, L., Bittencourt, R., Paz, A. Hospital de Clınicas
de Porto Alegre, Porto Alegre, RS, Brazil.
Patient’s age, stage of underlying disease, graft-versus-host dis-
ease, infections, and number of cells infused are among the multiple
variables that affect outcome of Allogeneic Stem-cell Transplanta-
tion (Allo-SCT). However, impact of socioeconomic status (SeS) is
still to be defined. The aim of the present study was to assess the SeS
influence on the outcome of allo-SCT. Two hundred and four
patients submitted to HLA-identical related Allo-SCT were retro-
spectively studied. Median age was 33 years. One hundred sixty-six
patients had malignancies (CML 68, ALL/AML 63, MDS 12,
others 23), and one hundred and forty-one patients were CMV pos-
itive. Graft-versus-Host Disease (GVHD) prophylaxis was cyclo-
sporine 1 methotrexate in 147 patients. Socioeconomic status (A
to E, being A the highest and E the lowest level) was adapted
from the Brazilian Association of Market Research Agencies classifica-
tion. Sixty-six, eighty three and fifty-five patients were classified as
A1B (higher SeS), C (intermediate), and D1E (lower SeS) socio-
economic status, respectively. Median time to neutrophil and plate-
let engraftment was 19 and 18 days, respectively. Cumulative
incidence of aGVHD grade 2–4 and cGVHD were 28.5% and
28.4% respectively. Transplant-related mortality (TRM at day
100) was 22.5%. Variables influencing TRM on univariate analysis
were: SeS, use of BuCy and use of TBI. To belong to D1E SeS was
associated with a higher TRM in multivariate analysis (HR5 2.96;
P 5 0.009). Estimated overall survival (OS) at 5 years was 52.4%.
On univariated analysis, SeS, age, CMV serology status, and a low
risk for relapse influenced OS. A D1E SeS (HR 5 4.34; P \
0.001) was associated with a worst outcome onmultivariate analysis.
In conclusion, a lower socioeconomic status is a strong prognostic
factor in patients undergoing allo-SCT in Brazil, influencing
TRM and overall survival.296
SIMULTANEOUS HAPLOIDENTICALLY MISMATCHED STEM CELL TRANS-
PLANTATION FROM MULTI-DONORS (MDT) IN HUMANS OFFERS BET-
TER ENGRAFTMENT AS COMPARED TO SINGLE HAPLOIDENTICAL
DONOR
Shapira, M.Y., Resnick, I.B., Gesundeheidt, B., Samuel, S., Drey, L.,
Verkholevsky, Y., Slavin, S., Or, R. Hadassah University Hospital, Jer-
usalem, Israel.
Introduction: : For patients with nomatched sibling available for
allogeneic SCT (approximately 70% of patients) an alternative op-
tion is SCT from a relative carrying only one identical HLA haplo-
type (haplo-SCT), which may provide a donor for almost every
patient at optimal timing. We hypothesized that simultaneous
transplantation from 2 donors may improve the engraftment fol-
lowing haplo-SCT. Patients and Methods: : Fifteen ultra high-
risk patients (median age 20 y, 9–52, mostly after 1–2 previous
SCTs and 13 of them with refractory disease) were included. Con-
ditioning regimen was fludarabine based. All grafts were T cell de-
pleted. Results: : All 14 evaluable patients engrafted but one of
them later rejected the graft. The time for neutrophil engraftment
(0.5 & 1.0  109/L) was fast, 11 d (9–24) and 12 d (10–28) respec-
tively. Platelets engrafted even earlier (20 & 100  109/L), 10
d (8–45) and 14 d (12–32) respectively. Three patients demonstrate
continuous bi-donor hematopoiesis (follow up 72, 128 and 168 d)
while 11 patients converted to single donor hematopoiesis within
a median of 21 d (14–39). Comparison of MDT patients to an ear-
lier patient group receiving a similar protocol with a single donor
(SDT) showed better granulocyte and platelet engraftment (p \
0.001 for both). Additionally, no primary graft failure occurred in
patients undergoing MDT, while in SDT it occurred in 9/38 pa-
tients (p \ 0.001). One patient in-which leukemia persisted
throughout the conditioning, leukemic cells disappeared upon the
conversion to single donor chimerism. Despite major blood type
differences, no hemolysis related side-effects were noted. Eight pa-tients developed GVHD (mostly grade 1/2).Conclusion: : MDT is
safe and induces fast and durable engraftment of both myeloid and
thrombocyte lineages in patients undergoing haplo-SCT. Further
studies should follow this report.297
SALVAGE TRANSPLANTATION FOR ALLOGRAFT FAILURE UTILIZING
FLUDARABINE AND ALEMTUZUMAB AS THE CONDITIONING REGIMEN
Bolan˜os-Meade, J., Luznik, L., Jones, R.J., Fuchs, E.J. The Sidney Kim-
mel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Graft failure remains a cause for elevatedmorbidity andmortality
after myeloablative allogeneic stem cell transplantation. This report
includes the outcome of nine patients that received a salvage alloge-
neic stem cell transplant after failing (rejecting) one (n5 8) or two (n
5 1) previous transplants. Three weremales and themedian age was
48.5. Diagnoses included: CMML 2, AML 2, CML 1, CLL 1, HL
1, NHL 1 and MDS 1. Median time between failed and salvage
transplant was 62 days (range 43–84). Patients received fludarabine
30 mg/m2 IV and alemtuzumab 20 mg IV every day from day -6 to
day -2. On day -2 they started cyclosporine 5 mg/kg IV over 6 hours
every day (n 5 8) or tacrolimus 1 mg PO every 12 hours (keeping
levels 5–15 ng/mL after 72 hours)(n 5 1). Day 0 was the infusion
of donor stem cells. By day 13, cyclosporine was decreased to 2.5
mg/kg IV and eventually switched to oral form once tolerated. Pa-
tients received G-CSF support until neutrophil recovery. Grafts
consisted of allogeneic HLA identical PBSC from a sibling in 6
cases,MUDPBSC in 2 andMUDBM in 1. All the patients received
the grafts from the same donor as in their previous transplant except
1. All patients engrafted. Neutrophil recovery was seen at a median
of 12 days. Seven patients achieved 100% chimerism by restriction
length fragment polymorphism by day 60, 1 by day 30, and 1 died
before chimerism evaluation but with neutrophil recovery. The
therapy was well tolerated with low toxicity. There are so far only
two cases of GVHD; one patient had skin only (acute grade II),
and the second had acute of the skin (grade II) and later chronic
of the skin (mild chronic/limited). With a median overall survival
of 191 days (range 37–738), six patients are alive and in complete re-
mission, three patients have died: two of relapse and one of a fungal
infection in the setting of GVHD therapy. The combination of flu-
darabine and alemtuzumab appears to be an effective and well toler-
ated conditioning regimen for reconditioning patients suffering
from graft failure.298
HIGHER CD 34 CELL DOSES REDUCE NON RELAPSE MORTALITY (NRM)
AND DO NOT INCREASE THE INCIDENCE OF GRAFT VERSUS HOST DIS-
EASE (GVHD) FOLLOWING UNRELATED DONOR BLOOD STEM CELL
TRANSPLANTATION (SCT)
Narayanan, S., Barnett, M.J., Abou Mourad, Y.R., Forrest, D.L.,
Hogge, D.E., Lavoie, J.C., Nantel, S.H., Shepherd, J.D., Song, K.W.,
Sutherland, H.J., Toze, C.L., Smith, C.A., Power, M., Nevill, T.J.
BC Cancer Agency and University of British Columbia, Vancouver,
BC, Canada.
Background: : Higher CD34 cell doses have been shown to in-
crease the incidence of acute (Przepiorka D et al, 1999) and exten-
sive chronic GVHD (Zaucha et al, 2001) following HLA-matched
sibling SCT. Less is known about the influence of CD 34 cell
dose in the unrelated SCT setting.Methods:A retrospective review
was performed involving 81 consecutive adult patients (pts) who un-
derwent unrelated donor G-CSF mobilised blood SCT in Vancou-
ver between June 2000 and October 2006. NRM, relapse risk (RR)
and overall survival (OAS) estimates were determined using a Ka-
plan-Meier technique and univariate and multivariate analyses
were done to identify factors predictive of GVHD and outcome,
with particular focus on cell dose administered. Characteristics:
There were 46 male and 35 female pts with a median age of 44
(range 17–58) years. Diagnoses included acute leukemia (39 pts),
chronic leukemia (14 pts), lymphoma (15 pts) and other (13 pts).
